Tangshen formula attenuates hepatic steatosis by inhibiting hepatic lipogenesis and augmenting fatty acid oxidation in db/db mice

International Journal of Molecular Medicine

Volumn 38, Issue 6, 2016, Pages 1715-1726

  Kong, Qin ^a,b   Zhang, Haojun ^b   Zhao, Tingting ^b   Zhang, Weiku ^b   Yan, Meihua ^b   Dong, Xi ^b   Li, Ping ^a,b  

^a GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^b CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Fatty acid oxidation; Hepatic steatosis; Lipogenesis; Tangshen formula

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DEHYDROGENASE; CD36 ANTIGEN; CHINESE DRUG; ESTROGEN RELATED RECEPTOR ALPHA; FATTY ACID SYNTHASE; GLUCOSE; GLUCOSE 6 PHOSPHATASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LIPOPROTEIN LIPASE; LIVER X RECEPTOR ALPHA; MALONYL COENZYME A DECARBOXYLASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TANGSHEN FORMULA; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; FATTY ACID; HERBACEOUS AGENT; TARGET OF RAPAMYCIN KINASE;

ACADM GENE; ACC GENE; ACC1 GENE; ACOX1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CPT1A GENE; CPT1B GENE; DB/DB MOUSE; DOWN REGULATION; ENZYME PHOSPHORYLATION; ESRRA GENE; FAS GENE; FAT GENE; FATTY ACID OXIDATION; FATTY LIVER; G6PC GENE; GENE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOLOGY; HMGCR GENE; IMMUNOHISTOCHEMISTRY; LIPOGENESIS; LIVER FUNCTION; LIVER WEIGHT; LPL GENE; LXR ALPHA GENE; MALE; MOUSE; NONHUMAN; PCK1 GENE; PGC1 ALPHA GENE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCD1 GENE; SIRT1 GENE; TFAM GENE; TRANSCRIPTION INITIATION; UPREGULATION; WEIGHT GAIN; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; GLUCONEOGENESIS; LIPID METABOLISM; LIVER; LIVER FUNCTION TEST; METABOLISM; MITOCHONDRION; OXIDATION REDUCTION REACTION; PATHOLOGY; SKELETAL MUSCLE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BIOMARKERS; BODY WEIGHT; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; FATTY ACIDS; FATTY LIVER; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCONEOGENESIS; LIPID METABOLISM; LIPOGENESIS; LIVER; LIVER FUNCTION TESTS; MALE; MICE; MITOCHONDRIA; MUSCLE, SKELETAL; OXIDATION-REDUCTION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TOR SERINE-THREONINE KINASES;

EID: 84999273593     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2799     Document Type: Article

References (43)

1. Smyth S and Heron A: Diabetes and obesity: The twin epidemics. Nat Med 12: 75-80, 2006.
2. Loomba R and Sanyal AJ: The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10: 686-690, 2013.
3. Ruderman NB, Carling D, Prentki M and Cacicedo JM: AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest 123: 2764-2772, 2013.
4. Fu L, Bruckbauer A, Li F, Cao Q, Cui X, Wu R, Shi H, Zemel MB and Xue B: Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice. Metabolism 64: 1426-1434, 2015.
5. Lian Z, Li Y, Gao J, Qu K, Li J, Hao L, Wu S and Zhu H: A novel AMPK activator, WS070117, improves lipid metabolism discords in hamsters and HepG2 cells. Lipids Health Dis 10: 67, 2011.
6. Lee JH, Jung JY, Jang EJ, Jegal KH, Moon SY, Ku SK, Kang SH, Cho IJ, Park SJ, Lee JR, et al: Combination of honokiol and magnolol inhibits hepatic steatosis through AMPK-SREBP-1 c pathway. Exp Biol Med (Maywood) 240: 508-518, 2015.
7. Jeon TI and Osborne TF: SREBPs: Metabolic integrators in physiology and metabolism. Trends Endocrinol Metab 23: 65-72, 2012.
8. Han J, Li E, Chen L, Zhang Y, Wei F, Liu J, Deng H and Wang Y: The CREB coactivator CRTC2 controls hepatic lipid metabolism by regulating SREBP1. Nature 524: 243-246, 2015.
9. Ponugoti B, Kim DH, Xiao Z, Smith Z, Miao J, Zang M, Wu SY, Chiang CM, Veenstra TD and Kemper JK: SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 285: 33959-33970, 2010.
10. Hou X, Xu S, Maitland-Toolan KA, Sato K, Jiang B, Ido Y, Lan F, Walsh K, Wierzbicki M, Verbeuren TJ, et al: SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283: 20015-20026, 2008.
11. Musso G, Gambino R and Cassader M: Emerging molecular targets for the treatment of nonalcoholic fatty liver disease. Annu Rev Med 61: 375-392, 2010.
12. Zhang H, Li P, Burczynski FJ, Gong Y, Choy P, Sha H and Li J: Attenuation of diabetic nephropathy in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with a combination of Chinese Herbs (Tangshen Formula). Evid Based Complement Alternat Med 2011: 613737, 2011.
13. Huang MC. Z, Liang QL, Li P, Li J, Wang YM and Luo GA: Effect of Tangshen Formula on phospholipids metabolism in diabetic nephropathy patients. Acta Pharmacol Sin 46: 780-786, 2011.
14. Tiniakos DG, Vos MB and Brunt EM: Nonalcoholic fatty liver disease: Pathology and pathogenesis. Annu Rev Pathol 5: 145-171, 2010.
15. Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, Jin X, Gao J, Li J, Fang H, et al: Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: A multicenter double-blinded randomized placebo-controlled trial. PLoS One 10: e0126027, 2015.
16. Reagan-Shaw S, Nihal M and Ahmad N: Dose translation from animal to human studies revisited. FASEB J 22: 659-661, 2008.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA and Bacon BR: Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 94: 2467-2474, 1999.
18. Sun SF, Zhao TT, Zhang HJ, Huang XR, Zhang WK, Zhang L, Yan MH, Dong X, Wang H, Wen YM, et al: Renoprotective effect of berberine on type 2 diabetic nephropathy in rats. Clin Exp Pharmacol Physiol 42: 662-670, 2015.
19. Quan HY, Kim Y, Kim SJ, Jo HK, Kim GW and Chung SH: Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway. Biochem Pharmacol 85: 1330-1340, 2013.
20. Schmittgen TD and Livak KJ: Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108, 2008.
21. Castaño D, Larequi E, Belza I, Astudillo AM, Martínez-Ansó E, Balsinde J, Argemi J, Aragon T, Moreno-Aliaga MJ, Muntane J, et al: Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation. J Hepatol 60: 1017-1025, 2014.
22. Jung EJ, Kwon SW, Jung BH, Oh SH and Lee BH: Role of the AMPK/SREBP-1 pathway in the development of orotic acid-induced fatty liver. J Lipid Res 52: 1617-1625, 2011.
23. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, et al: AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 13: 376-388, 2011.
24. Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X and Li X: Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab 9: 327-338, 2009.
25. Grefhorst A, Elzinga BM, Voshol PJ, Plösch T, Kok T, Bloks VW, van der Sluijs FH, Havekes LM, Romijn JA, Verkade HJ and Kuipers F: Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J Biol Chem 277: 34182-34190, 2002.
26. Sim WC, Park S, Lee KY, Je YT, Yin HQ, Choi YJ, Sung SH, Park SJ, Park HJ, Shin KJ and Lee BH: LXR-α antagonist meso-dihydroguaiaretic acid attenuates high-fat diet-induced nonalcoholic fatty liver. Biochem Pharmacol 90: 414-424, 2014.
27. Foster DW: Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J Clin Invest 122: 1958-1959, 2012.
28. Derdak Z, Villegas KA, Harb R, Wu AM, Sousa A and Wands JR: Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol 58: 785-791, 2013.
29. Wang C, Hu L, Zhao L, Yang P, Moorhead JF, Varghese Z, Chen Y and Ruan XZ: Inflammatory stress increases hepatic CD36 translational efficiency via activation of the mTOR signalling pathway. PLoS One 9: e103071, 2014.
30. Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, et al: SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab 15: 675-690, 2012.
31. Yamauchi T, Kamon J, Waki H, Imai Y, Shimozawa N, Hioki K, Uchida S, Ito Y, Takakuwa K, Matsui J, et al: Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278: 2461-2468, 2003.
32. Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, et al: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8: 1288-1295, 2002.
33. Moreno-Aliaga MJ, Pérez-Echarri N, Marcos-Gómez B, Larequi E, Gil-Bea FJ, Viollet B, Gimenez I, Martínez JA, Prieto J and Bustos M: Cardiotrophin-1 is a key regulator of glucose and lipid metabolism. Cell Metab 14: 242-253, 2011.
34. McGarry JD, Mannaerts GP and Foster DW: A possible role for malonyl-CoA in the regulation of hepatic fatty acid oxidation and ketogenesis. J Clin Invest 60: 265-270, 1977.
35. Zhang J, Zhang LN, Chen DM, Fu YY, Zhang F, Yang LL, Xia CM, Jiang HW, Tang CL, Xie ZF, et al: 2-(3-Benzoylthioureido)-4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid ameliorates metabolic disorders in high-fat diet-fed mice. Acta Pharmacol Sin 36: 483-496, 2015.
36. Lamming DW and Sabatini DM: A Central role for mTOR in lipid homeostasis. Cell Metab 18: 465-469, 2013.
37. Soliman GA: The integral role of mTOR in lipid metabolism. Cell Cycle 10: 861-862, 2011.
38. Yecies JL, Zhang HH, Menon S, Liu S, Yecies D, Lipovsky AI, Gorgun C, Kwiatkowski DJ, Hotamisligil GS, Lee CH and Manning BD: Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 14: 21-32, 2011.
39. Birkenfeld AL and Shulman GI: Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 59: 713-723, 2014.
40. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD and Parks EJ: Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115: 1343-1351, 2005.
41. Koonen DP, Jacobs RL, Febbraio M, Young ME, Soltys CL, Ong H, Vance DE and Dyck JR: Increased hepatic CD36 expression contributes to dyslipidemia associated with diet-induced obesity. Diabetes 56: 2863-2871, 2007.
42. Lee GY, Kim NH, Zhao ZS, Cha BS and Kim YS: Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: A key regulation of malonyl-CoA level. Biochem J 378: 983-990, 2004.
43. Zhu LH, Wang A, Luo P, Wang X, Jiang DS, Deng W, Zhang X, Wang T, Liu Y, Gao L, et al: Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice. J Hepatol 60: 1046-1054, 2014.